Related Experiment Video
Updated: Jul 19, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma
Paul G Richardson1, Constantine Mitsiades, Irene Ghobrial
1Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. Paul_Richardson@dfci.harvard.edu
Current Opinion in Oncology
|September 22, 2006
Summary
Bortezomib combinations show promise for relapsed or refractory multiple myeloma, improving response rates and survival. These regimens are effective across diverse patient groups and manageable.
Area of Science:
- Hematology
- Clinical Oncology
- Pharmacology
Background:
- Multiple myeloma treatment is evolving, with a focus on improving outcomes in relapsed or refractory settings.
- Bortezomib is a proteasome inhibitor with established efficacy in multiple myeloma.
Purpose of the Study:
- To review recent clinical trial data on bortezomib-based combinations in relapsed or refractory multiple myeloma.
- To discuss the implications of these combinations for patient outcomes and treatment strategies.
Main Methods:
- Review of recent clinical trial data.
- Analysis of response rates, survival data, and toxicity profiles.
Main Results:
- Bortezomib combinations demonstrate enhanced response rates, including complete responses, in relapsed/refractory multiple myeloma.
- Efficacy is observed across various patient subgroups, including elderly, those with adverse prognostic factors, and renal impairment.
- Toxicities are manageable and comparable to bortezomib monotherapy.
Conclusions:
- Bortezomib-based combinations show significant activity and can reverse chemoresistance in relapsed/refractory multiple myeloma.
- High response rates translate to improved survival, suggesting a substantial impact on the multiple myeloma treatment landscape.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...